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Abstract
Background: Middle-preserving pancreatectomy (MPP) is a parenchyma-sparing surgical procedure which has
recently been sporadically reported for the treatment of multicentric periampullary-pancreatic lesions. However, a
comprehensive recognition of this procedure has not been clearly elucidated.
Case presentation: We herein report two patients undergoing MPP due to synchronous multicentric pancreatic
neoplasm. Patient one was a 24-year-old woman with a multicentric solid pseudopapillary neoplasm (SPN) and
patient two was a 36-year-old woman with a multicentric serous cystic neoplasm (SCN). Simultaneous atypical
pancreaticoduodenectomy and atypical left pancreatectomy were performed in patient one; simultaneous standard
pancreaticoduodenectomy and atypical left pancreatectomy with spleen preservation were performed in patient
two. Approximately 6 cm and 5 cm segments of the middle portion of the pancreas were preserved, respectively.
At follow-up at 36 months and 6 months respectively, patient one had developed diabetes and malabsorption
requiring dietary control, exercise and pancreatic enzyme supplement whereas patient two showed normal fasting
blood glucose without diarrhea. Both patients were disease-free and in good nutritional condition. We reviewed
twenty cases of MPP that were previously reported in the literature. Patient characteristics, surgical techniques and
short- and long-term outcomes were analyzed.
Conclusion: MPP is mainly beneficial for multicentric noninvasive periampullary-pancreatic lesions. However, for
multicentric periampullary-pancreatic lesions involving even primary invasive cancers, as long as the invasive
cancers affect only one side of the pancreas (proximal or distal), MPP could serve as a rational choice in well-
selected patients.
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Background
In recent years, there has been an increasing interest in
parenchyma-sparing pancreatic surgery for benign, bor-
derline and low-grade malignant lesions involving isolated
or multicentric portions of the pancreas, especially in
young patients with long life expectancies. The aim is of
preserving exocrine and endocrine pancreatic function,
and achieving a better quality of life after operation [1-3].
Middle-preserving pancreatectomy (MPP) is a surgical
procedure recently advocated as treatment for multicentric
periampullary-pancreatic lesions in which the middle por-
tion of the pancreas is unaffected; it serves as an alternative
to total pancreatectomy (TP) with the goal of preventing
ensuing endocrine or exocrine pancreatic insufficiency
after TP without compromising oncological resection.
MPP is composed of either two pancreatic surgical ap-
proaches simultaneously (one-stage) or as a two-stage
method; one approach for lesions located in the pancreatic
head and periampullary region - the pylorus-preserving
pancreaticoduodenectomy (PPPD) for example, and the
other - which is the atypical left pancreatectomy (LP)
[1,4-13], is for lesions confined to the pancreatic body/tail
region. However, due to the rarity of suitable cases, MPP is
a very uncommon surgical procedure, resulting in difficulty
in elucidating its place in pancreatic surgery.
In this present article, the authors presented their own
experience of two patients undergoing simultaneous
MPP. In addition, a review of the literature on MPP
published in English is included, in this report, with the
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aim of presenting a comprehensive recognition of MPP
by analyzing its indications, surgical techniques, postop-




A 24-year-old woman was admitted to our department
for the evaluation and treatment of a pancreatic mass
which was found incidentally in a health check-up four
months previously. She had no associated symptoms and
her past medical history was unremarkable.
Physical examination was negative. Routine blood tests,
liver function tests, pancreatic enzymes levels and serum
tumor markers were all in the normal range. Body mass
index was 20.3 kg/m2 (52 kg/1.6 m2). Abdominal com-
puted tomography (CT) was performed, which showed
two well-defined, low attenuation masses with peripheral
enhancement and complex cystic components with areas
of necrosis and calcification in the head and the tail of the
pancreas (Figure 1a-c).
The patient was diagnosed with a multicentric solid
pseudopapillary neoplasm (SPN). Due to the low malig-
nant nature of SPN, a surgical procedure consisting of
pancreaticoduodenectomy (PD) and atypical LP with
splenectomy was planned. During operation, two tumors
located in the head and the tail of the pancreas were
identified; the distal pancreatic stump along with splenic
vessels was stapled about 2 cm proximal to the pancre-
atic tail tumor. An approximate 6 cm segment of normal
pancreatic tissue was preserved after a simultaneous
atypical PD and atypical LP (that is, transection line not
to portal vein/superior mesenteric vein) with splenec-
tomy was performed (Figure 1d). Diagnosis of SPN for
both tumors was made and the proximal and distal mar-
gins were demonstrated to be negative for tumor by
intraoperative frozen section. For the proximal pancreatic
stump, a retrocolic, two-layer, end-to-side invagination
pancreaticojejunostomy (PJ) and a one-layer, end-to-side
hepaticojejunostomy were performed, followed by a two-
layer end-to-end antecolic gastrojejunostomy. Both of the
tumors arising from two foci were diagnosed as SPN at
final pathological examination. The estimated entire nor-
mal pancreatic volume was 36.6 cm3 and about 47.2% of
normal parenchyma was preserved (20.2 cm3) through CT
volumetric assessment.
The postoperative course was uneventful. Postoperative
blood glucose levels ranged from 5.5 to 11.2 mmol/L and
the fasting blood glucose was 5.1 mmol/L one month






Figure 1 CT scans and intraoperative imaging of patient one. a) Plain CT revealed two well-defined heterogeneous lesions: calcification was
shown in the pancreatic head tumor (white arrow) and a septum was shown in the tail tumor (black arrow). b) Enhanced CT showed peripheral
enhancement and complex cystic components with areas of necrosis; calcification (white arrow) and septum (black arrow) were clearer (arrow).
c) Enhanced CT scan in portal phase. d) After a simultaneous atypical PD and atypical LP, about 6 cm of the pancreatic body was preserved (Pan),
proper hepatic artery (black arrow) and the stapled stump of the splenic vein (white arrow) can be seen. D, duodenum; G, gallbladder; Pan,
Pancreas; T, tumor.
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malabsorption 34 months after surgery, but her gly-
cemic control was achieved by diet and exercise, and
diarrhea was controlled by pancreatic enzyme supple-
ment. To date, 36 months disease-free survival has
been observed with no weight loss.
Case two
A 36-year-old woman was found incidentally in a health
check-up to have multicentric pancreatic cystic lesions
measuring 23 mm and 24 mm in diameter. These were
located synchronously in the head and the tail, respect-
ively. She was asymptomatic and her past medical history
was unremarkable. Multicentric serous cystic neoplasm
(SCN) was diagnosed and the patient was followed-up
with three-monthly US scans. During the follow-up, a
slight, progressive increase in tumor diameter was appar-
ent on subsequent US evaluation. After 27 months, the le-
sions were 31 mm and 40 mm in diameter respectively
and the patient began to experience upper abdominal dis-
comfort. Due to the increasing size of the lesions and her
symptoms, she was then admitted to our department for
treatment of the pancreatic mass. A further CT scan
showed two well-defined cystic lesions located in the head
and tail of the pancreas (Figure 2a-c). Her routine labora-
tory tests were within normal range, including serum
tumor markers CEA and CA19-9. Body mass index was
20.1 kg/m2 (58 kg/1.7 m2) on admission.
Considering the natural biological behavior of SCN, a
more conservative procedure was planned preopera-
tively: duodenum-preserving pancreatic head resection
(DPPHR) for tumor located in the head and spleen-
preserving atypical LP for tumor in the tail. On laparot-
omy, however, the lesion in the head was found to be
strongly attached to the descending duodenum, making
DPPHR impossible. Consequently, we performed a stand-
ard PD and spleen-preserving atypical LP for this patient.
The proximal and distal margins were demonstrated to be
negative for tumor by intraoperative frozen section. An
approximate 5 cm segment of normal pancreatic tissue
was preserved in this patient (Figure 2d). During the re-
construction phase, in contrast to patient one, end-to-side,
duct-to-mucosa PJ was applied; however, the remaining
reconstruction was the same as in patient one. Diagnosis
of SCN for both tumors was confirmed at pathological
examination. The estimated entire normal pancreas
volume was 47.8 cm3 and about 50.8% of normal par-
enchyma was preserved (24.3 cm3) through CT volu-
metric assessment.
The patient developed delayed gastric emptying (DGE)
which was managed successfully in a conservative way






Figure 2 CT scans and intraoperative imaging of patient two. a) Plain CT revealed two well-defined cystic lesions (white arrow). b) Enhanced
CT demonstrated polycystic appearance of the tumor with no enhancement in the arterial phase (white arrow). c) Enhanced CT demonstrated
polycystic appearance of the tumor with no enhancement in portal phase (white arrow). d) After a simultaneous standard PD and spleen-
preserving atypical LP, about 5 cm of the pancreatic body (Pan) and the splenic vein (arrow) were preserved. Pan, pancreas; PHA, proper hepatic
artery; PV, portal vein.
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endocrine pancreatic insufficiency has been observed so
far. The patient is also in good condition, takes no di-
gestive enzymes, has no diarrhea and her blood glucose
was normal at the last examination with a fasting blood
glucose is 5.3 mmol/L.
Discussion
Recent trends in pancreatic surgery favor parenchyma-
sparing over radical resection, where appropriate, for
pancreatic lesions, and operations such as middle- pan-
createctomy (MP) and enucleation, have gained satisfac-
tory results in terms of achieving better functional
preservation without compromising oncological radicality
[2,3]. Traditionally, in dealing with multicentric pancreatic
lesions, TP has been the choice of surgery. However, the
need for this major and demanding operation should be
carefully balanced against patient life expectancy under an
apancreatic condition, together with short- and long-term
outcomes of this procedure. Actually, a national review in
the USA revealed that TP carried a 28% major complica-
tion and 8.5% overall mortality rate perioperatively [14].
Additionally, in long-term follow-up, the Mayo Clinic
found that 28% of patients after TP developed target
organ complications and chronic diarrhea, 79% experi-
enced episodic hypoglycaemia and 41% experienced severe
hypoglycaemia [15]. Weighing these facts, the rationality
of applying TP to multicentric periampullary-pancreatic
lesions should be revisited. While TP is mandatory for
multicentric invasive malignant lesions, it seems to be
too extensive for benign, borderline or low-grade ma-
lignant conditions, especially in young, otherwise
healthy, patients. Recently, a new surgical procedure,
named as middle-segment preserving pancreatectomy
by Miura et al. [1] in 2007 and MPP by Partelli et al.
[6] in 2009, was proposed as an alternative of TP in
well-selected patients [1,4-13].
To date, to the best of our knowledge, only 22 patients, in-
cluding ours, have undergone this procedure. From data
shown in Table 1, it is apparent that MPP is mainly accept-
able for muticentric periampullary-pancreatic benign, bor-
derline, low-grade malignant lesions and pancreatic
metastases from other tumors in which lymphadenectomy is
not necessary. However, six patients were diagnosed with
primary periampullary-pancreatic invasive cancer [1,4,11,12].
One major concern that might be raised is whether MPP
guarantees tumor-free margins and sufficiently extensive
lymph node dissection in these situations. According to the
surgical principles of treating pancreatic cancer [16], as long
as the multicentric invasive cancers do not affect both the
proximal and the distal portions of the pancreas, synchron-
ously or metachronously, MPP should be pursued whenever
possible since in theory, it would offer sufficient extent of re-
section and nodal clearance, as demonstrated in previous re-
ports [1,11,12]. Although a two-stage MPP was applied in
one patient who presented with multicentric metachronous
pancreatic adenocarcinoma [4], we would not advocate MPP
in such situations because it evidently betrays the oncological
surgical resection principle [16].
Despite multicentric noninvasive lesions being the per-
fect candidates for MPP, there has been an increasing
number of reports where either tumor relapse or new
primary lesions developed in the remnant pancreas after
a previous pancreatectomy in IPMNs, PETs and meta-
static RCC [17-19]. In order to avoid the recurrence in
the remnant pancreas after MPP, appropriate candidates
should be selected through careful preoperative evalu-
ation of malignant potential, and intraoperative frozen
section analysis of the two resection margins should be
performed as a routine. Furthermore, intraoperative US
would be helpful to identify all of the lesions and to con-
firm that the remnant was disease-free [6,7]. In a word,
MPP should be converted to an oncologically appropri-
ate operation if inadequate tumor resections are encoun-
tered intraoperatively.
Additionally, there might be another technical consider-
ation when performing MPP. It has been reported that
there is a relationship between the spleen and the endo-
crine pancreas on animal models [20,21]. Though the
mechanism of their relationship is yet to be elucidated,
splenocytes are considered to play an important role
through accelerating β-cell neogenesis [20] and supporting
endogenous β-cell recovery [21]. What is more, patients
who underwent LP with splenectomy for chronic pancrea-
titis were reported to develop diabetes mellitus (DM) at a
higher rate compared with those who underwent spleen-
preserving LP [22,23]. Govil and Imrie [22] reported that
splenic preservation was noted to reduce DM after LP to
15% compared with 56% after splenectomy at a median
follow-up of 48 months; similarly, Hutchins et al. [23]
concluded that DM developed in 43% patients with
splenic preservation compared with 72% when the spleen
was removed at median follow-up of 34 months. More re-
cently, data from a research [24] has supported an associ-
ation between trauma splenectomy and elevated mean
blood glucose level. Interestingly, in current studies, new-
onset DM and worsening DM were noted in 11.8% (2/7)
of patients with splenic preservation, whereas 40% (6/15)
of patients after splenectomy experienced new-onset DM.
Surprisingly, patients in the splenic preservation group
were older (median 67 years, range 36 to 83 years), which
is thought to incur a higher risk of developing DM, com-
pared with those in the splenectomy group (median 62
years, range 24 to 72 years). However, because of the in-
trinsic weaknesses of this study and the complexity of
reported factors contributing to the development of DM
after pancreatic resection [25], it is difficult to rationally
interpret these data in relation to the role of splenic pres-
ervation. Nevertheless, it seems beneficial to preserve the
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Table 1 Summary of reported cases of patients undergoing MPP (Continued)
Ours
one 24/F 2
head/tail SPN/SPN atypical PD/
atypical LPe/A
6 cm no yes yes
NED (36)
one 36/F 2 head/tail SCN/SCN PD/ atypical LPf/B 5 cm grade A DGE no no NED (6)
CP, chronic pancreatitis; DGE, delayed gastric emptying; DPPHR, duodenum-preserving pancreatic head resection; IPHR, inferior pancreatic head resection; IPMN, intraductal papillary mucinous neoplasm; bIPMN,
branch duct IPMN; mixIPMN, mix duct IPMN; mainIPMN, main duct IPMN; LP, left pancreatectomy; MPP, middle-preserving pancreatectomy; NA, not available; NED, no evidence of disease; NF-PET, nonfunctioning
pancreatic endocrine tumor; one, one-stage MPP; PD, pancreaticoduodenectomy; PDAC, pancreatic duct adenocarcinoma; PPPD, pylorus-sparing pancreaticoduodenectomy; RCC, renal cell carcinoma; SCN, serous cystic
neoplasm; SPN, solid pseudopapillary neoplasm; SSPD, substomach-preserving pancreaticoduodenectomy; two, two-stage MPP.
Reconstruction A, B, C, D: A, end-to-side pancreaticojejunostomy; B, end-to-side, duct-to-mucosa pancreaticojejunostomy; C, pancreaticogastrostomy; D, not available.
Postoperative endocrine insufficiency was defined as new-onset diabetes or preoperative insufficiency deteriorating. Postoperative exocrine insufficiency was defined as steatorrhea, weight loss requiring pancreatic
enzymes supplementation, or preoperative insufficiency deteriorating. adiabetes or exocrine insufficiency existed preoperatively; bpreoperative insufficiency improved after operation; cpreoperative insufficiency
deteriorated after operation.
d(ewiths splenectomy and fwithout); gin two-stage MPP, this operation is the previous one; hdied of malignant lymphoma.




















spleen during MPP if oncologically and technically pos-
sible, which needs further observation.
Generally, MPP requires a pancreaticoenteric recon-
struction where one stump drains the preserved pan-
creas leaving the other stump to be transected and
closed. Thus, both that anastomosis and the transected
and closed resection margin at the other stump are at
risk for leakage, a situation similar to MP in which two
sites with potential for pancreatic fistula formation exist
[3]. A recent comprehensive review regarding MP found
that rates of pancreatic fistula varied from 4% to 50%,
morbidity from 13% to 62%, reoperation from 0 to 12%,
and mortality from 0 to 3% [3]. In the current study
concerning MPP, the overall morbidity was 40.9% (9/22),
pancreatic fistula was 22.7% (5/22) and reoperation was
4.5% (1/22) with no mortality (Table 1), which is accept-
able and comparable with the outcomes of MP.
The main benefit of MPP is that it spares the unaffected
middle of the pancreas which might be sacrificed by TP.
Early in 1973, DiMagno et al. [26] published a classic re-
search which related the degree of malabsorption to the
severity of pancreatic enzyme insufficiency. They showed
that clinically significant malabsorption did not occur
until 85 to 90% of pancreatic enzyme output was lost.
With regard to the endocrine function, Slezak et al. [27]
concluded that there was usually little change in glycemic
control unless more than 80% of the pancreas was
resected in patients with a previously normal pancreas. As
reported by Yasuda et al. [28], the volume of the middle of
the pancreas, as measured by CT-based pancreatic
volumetry, was about 25% of the entire gland. So from
theoretical point of view, MPP can preserve enough par-
enchyma to reduce the risk of developing endocrine and
exocrine insufficiency in selected cases. In current
study, at a median follow-up of 18 months (range 6 to
118), 8 out of 22 patients (36.4%) developed postopera-
tive pancreatic exocrine and/or endocrine insufficiency
(Table 1), which was obviously acceptable considering
the apancreatic condition after TP. Furthermore, MPP
preserves the glucagon-secreting alpha cells located in
the pancreatic body, the loss of which is responsible
for postoperative hypoglycemic episodes, which is still
a difficult major problem after TP [15].
Conclusions
Despite obvious drawbacks such as limited numbers and
the heterogeneity of patients in the present article, it
shows that MPP is mainly suitable for multicentric nonin-
vasive periampullary-pancreatic lesions; for multicentric
periampullary-pancreatic lesions even involving primary
invasive cancers, MPP could serve as a rational choice in
well-selected patients as long as the invasive cancers affect
only one side of the pancreas.
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